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Background: Acute respiratory distress syndrome (ARDS) is a disease associated with a high mortality rate. The
initial phase is characterized by induction of inflammatory cytokines and chemokines and influx of circulating
inflammatory cells, including macrophages which play a pivotal role in the innate and adaptive immune responses
to injury. Growing evidence points to phenotypic heterogeneity and plasticity between various macrophage
activation states.
Methods: In this study, gene expression in alveolar macrophages and circulating leukocytes from healthy control
subjects and patients with ARDS was assessed by mRNA microarray analysis.
Results: Both alveolar macrophages and circulating leukocytes demonstrated up-regulation of genes encoding
chemotactic factors, antimicrobial peptides, chemokine receptors, and matrix metalloproteinases. Two genes, the
pro-inflammatory S100A12 and the anti-inflammatory IL-1 decoy receptor IL-1R2 were significantly induced in
both cell populations in ARDS patients, which was confirmed by protein quantification. Although S100A12 levels
did not correlate with disease severity, there was a significant association between early plasma levels of IL-1R2
and APACHE III scores at presentation. Moreover, higher levels of IL-1R2 in plasma were observed in non-survivors
as compared to survivors at later stages of ARDS.
Conclusions: These results suggest a hybrid state of alveolar macrophage activation in ARDS, with features of
both alternative activation and immune tolerance/deactivation.. Furthermore, we have identified a novel plasma
biomarker candidate in ARDS that correlates with the severity of systemic illness and mortality.
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Acute respiratory distress syndrome (ARDS) is a deadly
disease, with an incidence of roughly 200,000 cases per
year in the United States and a mortality rate of approxi-
mately 40% [1]. ARDS is characterized by marked hyp-
oxemia (PaO2/FiO2 < 300), diffuse bilateral infiltrates, and
decreased lung compliance either due to direct injury (e.g.,
pneumonia, aspiration) or indirect injury (e.g., sepsis,
pancreatitis, transfusion-related acute lung injury) [2-4].* Correspondence: tstandif@umich.edu
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unless otherwise stated.Following the initial injury, a stereotyped process of tis-
sue injury, inflammation, and alveolar capillary damage
evolves to a fibroproliferative phase [5]. During the in-
flammatory phase, resident immune cells in the lung
express pro-inflammatory chemokines and cytokines, which
in turn stimulates the influx of circulating inflammatory cells
into the interstitium and alveolar spaces [4].
Macrophages play a pivotal role in the innate and
adaptive immune responses during host defense and re-
sponse to injury. Recent research has uncovered distinctly
heterogeneous populations of macrophages, as well as
plasticity between different macrophage phenotypes [6].
This phenotypic polarization of macrophages is believed
to be a consequence of factors present within the cell’s. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Demographic and clinical data of microarray
study population
Control ARDS patients
Age 45.8 ± 8.31 46.72 ± 15.62
Male:Female 3:2 12:6
APACHE Score 66.44 ± 13.12
P/f ratio 107.33 ± 50.78
Ventilator-Free Days 14.67 ± 8.0
Organ Failure-Free Days 18.16 ± 10.97
Diagnosis
Pneumonia 6 (37.5%)
Aspiration 3 (18.75%)
Sepsis 7 (43.75%)
Pancreatitis 1 (6.25%)
Other 1 (6.25%)
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distinct macrophage phenotypes have been described.
Classically-activated macrophages (M1) are generally associ-
ated with an inflammatory environment and mediate
microbial phagocytosis, pro-inflammatory cytokine expres-
sion, and cellular immune responses [6,9,10]. Alternatively-
activated macrophages (M2) are anti-inflammatory in
nature, and are associated with tissue repair and humoral
immune responses [9-11]. A third macrophage phenotype,
referred to deactivation or immunoparalysis, can be
induced by repeated exposure to various pathogen-
associated molecular patterns (PAMPs) in-vitro (referred
to as immune tolerance) or during the systemic inflamma-
tory response in-vivo [12-14]. Macrophage deactivation
is characterized by suppression of pro-inflammatory cy-
tokines (e.g., TNF-α, IL-6, nitric oxide synthase-2) and
enhanced expression of anti-inflammatory molecules
(IL-10), and this phenotype has been described in circu-
lating blood monocytes isolated from critically ill patients,
including patients with sepsis [12,15-19]. Recent evidence
also points to the presence of phenotypic heterogeneity,
with a spectrum between classically activated, alternatively
activated, and deactivated macrophages, particularly in the
setting of chronic inflammatory states [10,20-22].
The identification of biomarkers correlating to disease
activity in ARDS is an important goal, potentially allowing
for earlier diagnosis and treatment, as well as providing
prognostic information [23]. Nevertheless, successful asso-
ciation of biomarkers to disease severity remains elusive.
S100 calcium binding protein A12 (S100A12) is a known
chemoattractant, and is a pro-inflammatory ligand for
the RAGE receptor [24]. Previous studies have found
that S100A12 protein is upregulated in both the bron-
choalveolar lavage (BAL) fluid and plasma of patients
with ARDS [25-27]. However, these studies did not as-
sess whether S100A12 levels correlated with indices of
ARDS severity. Conversely, the anti-inflammatory IL-1
decoy receptor, IL-1R2, has recently been shown to be
elevated in plasma during sepsis [28], as well as a mouse
model of chemically-induced lung injury [29]. However,
there have been no studies examining the association of
IL-1R2 and human lung disease, specifically ARDS.
In this pilot study, we analyzed gene expression profiles
in isolated alveolar macrophages (AM) obtained from
BAL samples and buffy coat leukocytes isolated from
patients with ARDS. As compared to cells from healthy
subjects, there was considerable over-representation of
immune activation genes, including genes involved in
leukocyte trafficking, phagocytosis, microbial killing, apop-
tosis and lymphocyte activation. We also found a gene ex-
pression profile in AM with features of both alternative
macrophage activation and immune tolerance/deactivation,
suggesting the presence of unique macrophage phenotypes
present early in the course of ARDS that may haveimportant functional significance in the pathogenesis
and course of disease in this patient population. Further-
more, we assessed plasma and BAL levels of two of the
most highly induced genes identified in our microarray
analysis, S100A12 and IL-1R2. While both analytes were
significantly up-regulated in both the plasma and BAL
fluid of ARDS patients as compared with healthy control
subjects, only plasma levels of IL-1R2 correlated signifi-
cantly with APACHE III scores and mortality. We have
therefore identified a novel plasma biomarker candidate
for ARDS, which may aid in early diagnosis and which car-
ries prognostic implications for disease severity in ARDS.
Materials and methods
Patient selection
Patients with ARDS that were enrolled in the Acute
Lung Injury Specialized Center of Clinically Oriented
Research randomized trial of granulocyte-macrophage
colony stimulating factor conducted at the University
of Michigan between July 2004 and October 2007 were
studied [30]. Samples from eighteen patients were in-
cluded in the microarray analysis, whereas samples from a
larger group of patients were used for measurement of
S100A12 and IL-1R2 quantitation. Criteria for ARDS were
as follows: Acute onset of illness with: 1) PaO2/FiO2 ≤ 300;
2) bilateral infiltrates consistent with pulmonary edema on
frontal chest radiograph; 3) requirement for positive pres-
sure ventilation via an endotracheal tube; 4) no clinical
evidence of left atrial hypertension; 5) if measured, pul-
monary arterial wedge pressure ≤ 18 mm Hg; and 6) the
aforementioned criteria occurring together within a 24-
hour interval. These subjects underwent serial bronchos-
copy with BAL and peripheral blood collection at various
time points post onset of ARDS. For the microarray ana-
lysis, a subset of 18 patients were studied. In this subset,
sample collection was performed between days 0–4 from
Table 2 Demographic and clinical data of study
participants
Control ARDS patients
Age 45.8 ± 8.31 47.2 ± 13.95
Male:Female 3:2 31:19
APACHE Score 58.12 ± 17.48
P/f ratio 128.4 ± 62.46
Ventilator-Free Days 12.26 ± 10.64
Organ Failure-Free Days 14.21 ± 12.52
Diagnosis
Pneumonia 14 (29.2%)
Aspiration 7 (14.6%)
Sepsis 18 (37.5%)
Pancreatitis 4 (8.3%)
Other 5 (10.4%)
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[30] and only samples collected from patients randomized
to the placebo control arm of the study or the observa-
tional study were utilized. Of the 18 patients enrolled in
the microarray sub-study, 17 patients had blood samples
drawn for buffy coat analysis, and 7 patients underwentFigure 1 Heat map for selected immune response genes expressed in i
control subjects. Each row represents a gene and each column represen
indicated at the bottom of the heat map. Red and blue indicate expressio
to the left of the matrix represents overall similarities in gene expressionbronchoscopy for the collection of BAL for AM analysis
[30,31]. Serial blood and BAL samples were also collected
from an additional 70 ARDS patients for a total of 88
samples analyzed for cytokine levels by ELISA. As with
microarray samples, only patients from the observational
or placebo arms were analyzed. A single blood and
BAL sample were collected from 5 healthy subjects fol-
lowing informed s and under protocols approved by the
University of Michigan Institutional Review Board, which
served as controls for both the microarray and ELISA
analyses. All control subjects were less than 55 years of
age, on no medications, and were life-long non-smokers.
Demographic and clinical data of the microarray study
population are summarized in Table 1. Demographic and
clinical data of the larger population are summarized in
Table 2.
Sample preparation
Peripheral whole blood samples were collected from ARDS
patients and healthy controls into heparin-containing
Vacutainer® tubes (Becton-Dickinson, Franklin, NJ, USA)
and centrifuged (1500 rpm for 10 minutes at room
temperature). The buffy coat cell layer was carefully as-
pirated and buffy coat cells were suspended in Trizol®solated alveolar macrophages from patients with ARDS vs. healthy
ts a sample. Patients are classified as control (blue) or ARDS (green) as
n levels above and below the median, respectively. The dendrogram
profiles.
Table 3 Top up- and down-regulated genes in alveolar
macrophages from ARDS patients as compared to controls
Gene Fold increase
(ARDS vs. Control)
Gene Fold decrease
(ARDS vs. Control)
S100a12 49.43 FABP4 −40.62
IL-1R2 35.5 RND3 −37.53
CD177 34.32 ITIH5 −24.76
CRISPLD2 27.88 C8a −22.89
OLFM4 25.24 FAM3B −21.14
HLA-DQA1 23.6 NALCN −20.03
Arginase1 19.16 SLC47α1 −19.12
IL-18R1 18.47 FHL1 −18.81
HLA-DRB1 18.09 VGLL3 −18.38
CYP1B1 17.68 HLA-DQB2 −17.83
MMP8 17.41 APO-C2 −16.77
ORM1 17.39 OASL −15.1
KCNJ15 17.33 HLA-DRB4 −14.85
Annexin A3 17.18 SERPIN-G1 −14.63
STEAP4 17.16 RBP4 −13.8
MRVI1 17.11 C8b −13.21
DYSF 16.47
IL-8RA 16.06
MCTP2 15.56
MMP25 14.59
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at −20°C. The remaining plasma was stored at −80°C.
Bronchoalveolar lavage fluid was obtained from control
subjects and ARDS patients by bronchoscopy using a
standard technique as previously described [30,31]. The
BAL was centrifuged (1500 rpm at 4°C for 10 minutes).
Cell free supernantant was removed and stored (−70°C).
Cells were resuspended and plated in plastic culture dishes
containing media (RPMI, manufacturer, state, USA). After
a one hour incubation (5% CO2, 37°C), non-adherent cells
were removed by washing, and adherent macrophages
were resuspended in Trizol® reagent and stored (−20°C).
Cell differentials post adherence revealed >90% macro-
phages by morphology, and highly expressed both CD163
and CD14. The mRNA expression of CD163 and CD14
by AM isolated from ARDS patients was not different
than that expressed by AM collected from control patients
(data not shown).
Microarray analysis
Frozen buffy coat and AM samples were shipped to
Centocor (Radnor, PA).
The quantity and purity of RNA were measured using
a Thermo Scientific NanoDrop 1000 Spectrophotometer
(NanoDrop technologies, Berlin, Germany) while the qual-
ity of RNA was determined by running aliquots on the
2100 Bioanalyzer (Agilent Technologies, Waldbronn,
Germany). Samples with a RNA integrity number <6.5
or a concentration <50 ng/μl were excluded from the
study while samples with a RNA integrity number ≥6.5
and a concentration ≥50 ng/μl were labelled. TotalRNA
was reverse transcribed and product cDNA amplified,
fragmented, and labelled using the Ovation RNA Amp-
lification and cDNA Biotin System (NuGen). Labelled
cDNA was hybridized to Affymetrix GeneChip HT HG-
U133+ PM Array plates. After washing and staining cell
files were produced from scanned images (High Through-
put Array Plate Scanner, Affymetrix) using Affymetrix
Control Console software.
ELISA
Cell-free BAL fluid and plasma from healthy controls and
ARDS patients were assayed for human IL-1R2 using a
Duo-Set ELISA (R&D Systems, Minneapolis, MN) and
S100A12 using a CircuLex EN-RAGE ELISA Kit (MBL
International, Woburn, MA). Assays were performed in
accordance with the manufacturers’ instructions.
Statistical analysis
Statistical analyses of microarrays were performed using
ArrayStudio Version 5.0 (Omicsoft, NC). Data were nor-
malized using robust multichip average method and log2-
transformed and assessed by probset intensity, principle
component analysis, hierarchical cluster analysis andsample correlation. General linear model with proper
contrast tests were used. Differential expressed genes
were identified using following criteria: a fold change of
at least 2, raw p-value < 0.01 and estimated least squares
mean intensity greater than or equal to 4 for at least one
group in the comparison. Corrected p values using the
Benjamini-Hochberg method were generated through the
use of IPA (Ingenuity® Systems, www.ingenuity.com) to
control for false discovery. Pathway and network analyses
were also generated through the use of IPA.
Plasma and BAL IL-1R2 and S100A12 ELISA data were
Log10 transformed and/or range scaled, as required, to
achieve normal distribution for the performance of para-
metric statistical tests. The mean normalized concentra-
tions of IL-1R2 and S100A12 in healthy controls were
compared to the respective mean concentrations of these
cytokines in ARDS patients using a one-way analysis of
variance followed by a Dunnett’s post-test for multiple
comparisons. The strength of associations between ARDS
patient plasma and BAL cytokine concentrations and
clinical phenotype data (e.g., APACHE III scores) were
determined by logistic regression analysis. Statistical
analyses were performed using GraphPad Prism 6.0
software for Windows (GraphPad Software, San Diego, CA).
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Inflammatory gene expression is increased in alveolar
macrophages of ARDS patients
Microarray analysis was performed on AM isolated from
BAL fluid of patients with ARDS and controls. As com-
pared to AM from non-diseased healthy control subjects,
229 probe sets were significantly up-regulated, whereas
344 probe sets were down-regulated in ARDS patients. A
heat map of representative immune response genes is
shown in Figure 1. The top up- and down-regulated genes
observed in ARDS patients are shown in Table 3. Over-
represented genes are primarily related to inflammatory,
immune and injury responses, phagocytosis, and commu-
nication between innate and adaptive immune cells. The
most highly expressed gene in the AM of ARDS patients
was the leukocyte chemoattractant, S100A12.
Data shown in Figure 2 represent up- and down-
regulated genes that are associated with various macro-
phage activational states. Of the top up-regulated genes,
several are characteristically expressed by alternatively ac-
tivated macrophages, including arginase-1 (19.2-fold in-
crease, p < 0.05), MHC Class II molecules (MHC-DRB1,
17.2-fold increase, p < 0.01), CCR2 (4.7-fold increase,
p = 0.07), and several of the matrix metalloproteinases,
including MMP8 (17.4-fold increase, p < 0.01), MMP9
(7.1-fold increase, p < 0.01) and MMP25 (14.6-foldFigure 2 mRNA expression of selected genes in alveolar macrophage
expressed as fold change compared to healthy control subjects. Mean
patients. (* p < 0.05 as compared to healthy subjects).increase, p < 0.01). Conversely, there was no significant
change (TNF-α, IL-6, nos-2) or a reduction (IFN-γ,
and the interferon-γ-inducible chemokines CXCL9 and
CXCL10; 3.1-, 11.3-, and 8.6-fold decrease respectively,
p < 0.05 for all) in the expression of genes associated
with classical or M1 macrophage activation. We also
observed preferential expression of genes associated
with macrophage deactivation or immune tolerance in
ARDS macrophages. Specifically, there was significantly in-
creased expression of IRAK-3 (3.2-fold increase, p < 0.01,
also referred to as IRAK-M) and trend toward enhanced
IL-10, and reduced expression of HLA-DRA. One of
the most highly expressed genes in ARDS macrophages
was IL-1R2 (35.5-fold increase, p < 0.01). IL-1R2 is a
non-signaling decoy receptor that functions to dampen
IL-1 mediated cell activation [32].
Gene expression in circulating buffy coat leukocytes of
ARDS patients
mRNA microarray analysis was also performed on buffy
coat cells isolated from peripheral blood of patients with
ARDS and healthy controls. As compared to control buffy
coat cells, 1885 probe sets were significantly up-regulated
and 2017 probe sets were significantly down-regulated in
ARDS samples. Gene groups identified as up-regulated in-
cluded those associated with leukocyte activation, cellulars of ARDS patients associated with macrophage activation states
fold change was calculated from 4 healthy controls and 7 ARDS
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oxidative phosphorylation), and B-cell, T-cell, and NK-cell
signaling pathways. A representative heat map is shown in
Figure 3.
The top up- and down-regulated genes expressed by
circulating leukocytes from ARDS patients are shown in
Table 4. Several members of the carcinoembryonic antigen-
related cell-adhesion molecule (CEACAM) family are not-
ably increased, namely CEACAM1, −6, and −8, members
of the immunoglobulin subfamily which are associated with
bacterial adhesion and cellular invasion. Additionally,
several neutrophil-derived antimicrobial peptides are up-
regulated, including alpha defensins, human bactericidal/
permeability-inducing protein (BPI), and the cathelicidin
CAMP.
Over- and underrepresented gene sets common to both
alveolar macrophages and peripheral blood buffy coat cells
A total of 48 known genes were significantly overex-
pressed and 18 genes down-regulated in both ARDS mac-
rophages and buffy coat cells as compared to control
subjects (Table 5). Common upregulated genes included
genes encoding chemotactic factors, antimicrobial peptides,Figure 3 Heat map for selected immune response genes expressed in
control subjects. Each row represents a gene and each column represent
indicated at the bottom of the heat map. Red and blue indicate expression
the left of the matrix represents overall similarities in gene expression profichemokine receptors and matrix metalloproteinases. Of
these up-regulated genes, S100A12, CD177, olfactomedin
4, and MMP8 were the most highly expressed in both
macrophages and buffy coats of ARDS patients. Notably,
the anti-inflammatory gene encoding IL-1R2 was also
markedly over-expressed in both cell populations during
ARDS.Determination of plasma and BAL fluid levels of IL-1R2
and S100A12 protein levels
We elected to focus on the top two up-regulated genes
in AM, IL-1R2 and S100A12, to confirm our microarray
findings. Protein levels of these two molecules in both
plasma and cell-free BAL fluid were analyzed by ELISA
in ARDS patients and healthy control subjects. IL-1R2
was significantly elevated in both the BAL fluid and plasma
of ARDS patients compared with healthy controls. This in-
crease was evident early in the course of ARDS (days 0–3),
and persisted up to 8–14 days after the onset of disease
(Figure 4). S100A12 was also significantly increased early
in both the plasma and BAL of ARDS patients (days 0–3)
and remained elevated in plasma for up to 90–180 daysbuffy coat leukocytes from patients with ARDS vs. healthy
s a sample. Patients are classified as control (blue) or ARDS (green) as
levels above and below the median, respectively. The dendrogram to
les.
Table 4 Top up- and down-regulated genes in buffy coats
from ARDS patients as compared to controls
Gene Fold increase
(ARDS vs. Control)
Gene Fold decrease
(ARDS vs. Control)
CEACAM6 24.78 CD28 −11.9
Defensin α-4 23.78 HDAC9 −8.64
Defensin α-1 23.52 CRTAM −8.06
CEACAM1 22.81 SERPINB9 −7.96
FCER1G 18.52 MSRA1 −6.85
CD14 18.45 TGFBR3 −6.55
ITGB2 14.86 GPR183 −6.45
THBS1 14.77 KLRC1/2 −6.19
BPI 14.18 CD96 −6.17
IFITM3 14.08 PTPRC −4.94
ARRB2 13.92 FAS Ligand −4.73
ITGB2 13.74 PRKRA −4.28
NCF4 13.61 ETS1 −4.06
VNN1 12.14 GZMA −3.91
FCGR1 Family 12.08 IL-15 −3.56
LILRA2 11.21
PGLYRP1 11.09
CAMP 10.45
CEACAM8 10.34
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(Figure 5B).
Correlation of biomarker levels to patient demographic data
Based on the observation that both IL-1R2 and S100A12
were significantly elevated in both plasma and BAL fluid
of ARDS patients as compared with healthy control
subjects, we compared levels of these molecules within
ARDS patients to demographic and clinical outcomes
data. Plasma IL-1R2 levels measured early (days 0–3) in
the onset of disease significantly correlated with the
APACHE III scores at the time of presentation to the
hospital (Figure 6A, p < 0.005, R2 value 0.2134). Although
plasma S100A12 levels increased with increasing APA-
CHE scores, this correlation did not meet the level of
statistical significance (Figure 6B). Neither BAL IL-1R2
nor S100A12 were significantly correlated with the initial
APACHE score. Interestingly, we also observed a signifi-
cant positive correlation between plasma IL-1R2 measured
at days 7–14 and initial APACHE III score. Mortality in
this study was low (<25%), Importantly, although, we did
not observe significant associations between plasma or
BAL IL-1R2 levels and survival in early ARDS,(peroids
between days 0–3 or 4–6) , we found that mean plasma
IL-1R2 levels measured between days 7–14 post ARDS
onset were significantly higher in non-survivors as
compared to survivors (Figure 7).Of note, we did not observe any statistically significant
correlations between either plasma or BAL biomarker
levels and other clinical phenotypic data including PaO2/
FIO2 (P/F) ratio, ventilator-free days, or organ failure-
free days (Additional file 1: Figure S1, Additional file 2:
Figure S2 and Additional file 3: Figure S3).Discussion
In this study, we sought to determine alterations in gene
expression in leukocyte populations of patients with ARDS.
In AM isolated from ARDS patients, many of the most
highly up-regulated genes are involved in inflammation
and immune responses to injury. CD177, which was also
up-regulated in both the AM and in buffy coat cells of
ARDS patients, is a molecule expressed by both activated
neutrophils and macrophages that interacts with the
PECAM-1 (platelet endothelial cell adhesion molecule 1),
indicating a role in leukocyte extravasation and trans-
migration into inflammatory environments [33]. We
also identified genes expressed in both AM and buffy
coat cells during ARDS that have not previously been
associated with pulmonary inflammation or injury. One
such gene is olfactomedin 4, a protein expressed in bone
marrow cells, tumor cells, and intestinal epithelium but
found to be highly over-represented in our ARDS patient
samples [34].
Although it was not unanticipated that we would ob-
serve an up-regulation of immune activation genes, it is
notable that we also found a gene expression pattern in
ARDS macrophages that displayed features of alternative
activation or immune tolerance/deactivation. For example,
arginase-1 was highly expressed in the AM of ARDS pa-
tients, and is a well-known product of alternatively AM.
MMP8, −9 and −25 were also significantly up-regulated,
and are associated with an alternative activation pheno-
type. There were also reciprocal decreases in genes that
drive or are associated with classical M1 macrophage
activation, including IFN-γ and IFN-γ-dependent CXC
chemokines CXCL9 and CXCL10. Additionally, macro-
phages from ARDS patients displayed a molecular sig-
nature of immune tolerance/deactivation. For example, we
observed no significant change or a trend toward reduced
expression of important NF-κB-dependent pro-inflammatory
cytokines, including TNF-α, IL-6, and IL-1β, whereas
there was enhanced expression of the toll-like receptor
signaling inhibitor IRAK-3 (IRAK-M) and a trend to-
ward increased IL-10 message. In addition to suppres-
sion of a variety of inflammatory genes (tolerizable genes),
an additional feature of LPS-tolerized macrophages is the
superinduction of non-tolerizable genes that are primarily
involved in host defense, including antimicrobial peptides
[15]. This pattern is mimicked in both AM and especially
buffy coat cells isolated from ARDS patients.
Table 5 Top up- and down-regulated genes common to both alveolar macrophages and buffy coats from ARDS patients
as compared to controls
Gene
symbol
Gene name ARDS vs. Control fold change
Alveolar macrophages Buffy coat
S100A12 S100 calcium binding protein A12 49.43 5.56
IL1R2 Interleukin 1 receptor, type II 35.5 9.66
CD177 CD177 molecule 34.32 44.84
MGAM Maltase-glucoamylase (alpha-glucosidase) 26.87 3.34
OLFM4 Olfactomedin 4 25.24 28.11
MMP8 Matrix metallopeptidase 8 17.41 31.96
ANXA3 Annexin A3 17.18 3.67
MRVI1 Murine retrovirus integration site 1 homolog 17.11 3.51
DYSF Dysferlin 16.47 14.24
CXCR1 Chemokine (C-X-C) receptor 1 16.06 4.66
PROK2 Prokineticin 2 15.09 2.79
MMP25 Matrix metallopeptidase 25 14.59 12.52
METTL7B Methyltransferase-like 7B 11.88 6.4
DEFA1 Defensin, alpha 1 11.43 23.52
GPR97 G protein-coupled receptor 97 11.07 9.29
F5 Coagulation factor V (proaccelerin) 9.79 6.45
LRG1 Leucine-rich alpha-2-glycoprotein 1 9.08 4.89
ADAM8 ADAM metallopeptidase domain 8 8.94 2.73
CSF3R Colony stimulating factor 3 receptor 8.85 7.88
ARAP3 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 8.75 4.51
RASSF2 Ras association (RalGDS/AF-6) domain family member 2 8.51 8.01
PADI2 Peptidyl arginine deiminase, type II 7.86 12.49
FGF13 Fibroblast growth factor 13 7.35 5.91
RNF175 Ring finger protein 175 7.17 2.96
PRKCB Protein kinase C, beta 7.01 7.02
PXN Paxillin 6.34 6.01
VNN1 Vanin 1 6.07 10.24
GAS7 Growth arrest-specific 7 5.28 3.5
TSNAX Translin-associated factor X 5.26 4.42
IFITM2 Interferon induced transmembrane protein 2 (1-8D) 5.21 9.44
GGT1 Gamma-glutamyltransferase 1 4.55 7.3
SIGLEC5 Sialic acid binding Ig-like lectin 5 4.45 7.57
BASP1 Brain abundant, membrane attached signal protein 1 4.2 2.8
MXD1 MAX dimerization protein 1 3.93 3.17
LMNB1 Lamin B1 3.78 4.13
CR1 Complement component (3b/4b) receptor 1 3.62 4.51
PSTPIP2 Proline-serine-threonine phosphatase interacting protein 2 3.37 2.9
GGTLC1 Gamma-glutamyltransferase light chain 1 3.28 3.3
PGS1 Phosphatidylglycerophosphate synthase 1 3.22 5.24
S100A8 S100 calcium binding protein A8 2.97 5.98
AQP9 Aquaporin 9 2.83 4.11
SLC22A4 Solute carrier family 22 (organic cation/ergothioneine transporter), member 4 2.83 3.17
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Table 5 Top up- and down-regulated genes common to both alveolar macrophages and buffy coats from ARDS patients
as compared to controls (Continued)
IL17RA Interleukin 17 receptor A 2.71 3.32
HDAC4 Histone deacetylase 4 2.66 4.25
ITGAM Integrin, alpha M 2.58 2.47
AGTRAP Angiotensin II receptor-associated protein 2.22 5.61
SMAP2 Small ArfGAP2 2.22 4.96
HLX H2.0-like homeobox 2.17 4.84
IMMP2L IMP2 inner mitochondrial membrane peptidase-like −2.06 −3.08
L3MBTL3 l(3)mbt-like 3 (Drosophila) −2.06 −2.34
CD3G CD3g molecule, gamma (CD3-TCR complex) −2.35 −2.47
PIGL Phosphatidylinositol glycan anchor biosynthesis, class L −2.4 −2.6
PLA2G16 Phospholipase A2, group XVI −2.68 −2.3
CCDC50 Coiled-coil domain containing 50 −2.71 −4.71
ICA1L Islet cell autoantigen 1,69 kDa-like −3.07 −3.74
ZNF124 Zinc finger protein 124 −3.11 −4.54
WWOX WW domain containing oxidoreductase −3.39 −3.81
EPB41L4A Erythrocyte membrane protein band 4.1 like 4A −3.41 −10.19
RORA RAR-related orphan receptor A −4.17 −7.89
YES1 v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1 −4.19 −4.55
RORA RAR-related orphan receptor A −4.21 −3.43
ZNF846 Zinc finger protein 846 −4.54 −2.31
SASH1 SAM and SH3 domain containing 1 −4.73 −4.29
ENPP5 Ectonucleotide pyrophosphatase/phosphodiesterase 5 (putative function) −5.72 −4.99
JAKMIP2 Janus kinase and microtubule interacting protein 2 −5.77 −2.77
TCEA3 Transcription elongation factor A (SII), 3 −7.57 −2.77
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expression suggesting a hybrid state of AM activation,
with features of both alternative activation and immune
tolerance/deactivation. This phenotype has not been de-
scribed previously in lung macrophages during ARDS. It
is possible that the phenotype observed represents a
heterogenous population of macrophages within the lung.
There is accumulating evidence of mixed macrophage
phenotypes in other disease states, particularly in chronic
inflammatory diseases [10,20-22]. It is not surprising that
macrophages would display a healer M2 phenotype within
the first 96 h post disease onset, which is consistent with
the notion that lung fibroproliferation and repair are initi-
ated early in the course of ARDS [35].
In addition to AM, we analyzed gene expression within
circulating leukocytes of patients with ARDS. This popula-
tion had a much broader range of differentially expressed
genes, as compared with the AM, which is not unexpected
given a more diverse cell population present in peripheral
blood buffy coats. Canonical pathways that were acti-
vated in ARDS buffy coat cells included those involved in
T-cell, B-cell, and NK-cell signaling, suggesting generalizedlymphocyte activation. Additionally, pathways involved in
leukocyte phagocytosis were over-represented, suggesting
activation of circulating phagocytes. Furthermore, there
were increases in integrin signaling and leukocyte ex-
travasation signaling, reflective of the known migration
of activated leukocytes to areas of inflammation.
Of potential genes that were up-regulated in AM and
circulating leukocyte of ARDS patients, we chose to focus
on two of the most highly induced genes, the proinflam-
matory cytokine S100A12 and the anti-inflammatory
decoy receptor IL-1R2. We found that the S100 protein,
S100A12, was the most highly expressed gene in lung
macrophages from ARDS patients compared to controls.
Notably, we also observed increases in S100A12 gene ex-
pression by circulating leukocytes of ARDS patients. This
mRNA expression pattern paralleled the increased protein
expression of S100A12 observed in both plasma and BAL
fluid of ARDS patients. S100A12 is a known chemoattract-
ant with an affinity for both neutrophils and monocytes,
and has been shown to be a ligand for the RAGE receptor
[24]. Although constitutively expressed in neutrophils
[36], its expression in monocytes/macrophages is induced
Figure 4 Expression of IL-1R2 protein in (A) plasma samples and (B) BAL fluid of ARDS patients vs. healthy control subjects. Protein levels were
quantified by ELISA. Column means were analyzed by ANOVA with Dunnett’s multiple comparisons test. (*p < 0.05 as compared to healthy subjects).
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(LPS) and TNFα.[37] Our observations are consistent with
the previously published findings of increased S100A12
protein in both the BAL fluid and plasma of patients with
ARDS [25-27]. While recognizing that S100A12 is up-
regulated in plasma and BAL fluid of ARDS patients, these
studies did not assess whether meaningful correlations
could be made between levels of S100A12 and ARDS
severity. We did not identify significant associations be-
tween this analyte and clinically relevant outcomes suchas mortality, which may be due to the relatively small
sample size and low observed mortality rate..
In addition to S100A12, we also observed strong
mRNA induction of the IL-1 decoy receptor, IL-R2, in
lung macrophages and buffy coat cells. IL-1R2 has a
short cytoplasmic domain lacking the Toll/IL-1R domain
required for intracellular signaling [38]. IL-1R2 regulates
the proinflammatory activities of IL-1 by competitively
binding to IL-1 at the cell surface and by sequestering
IL-1R accessory protein and inhibiting the formation of
Figure 5 Expression of S100A12 protein in (A) plasma and (B) BAL fluid of ARDS patients vs. healthy control subjects. Protein levels were
quantified by ELISA. Column means were analyzed by ANOVA with Dunnett’s multiple comparisons test. (*p < 0.05 as compared to healthy subjects).
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response to proinflammatory stimuli such as LPS or
TNFα, proteolytic cleavage of the membrane-bound por-
tion of IL-1R2 occurs, resulting in a soluble form which
is capable of sequestering IL-1 at sites of inflammation
[28,40,41]. Although the molecule has been shown to be
up-regulated in the setting of sepsis [28] as well as re-
cently in a mouse model of chemically-induced lung in-
jury [29], this gene has not previously been recognized
as a biomarker candidate of disease severity in humanARDS. In this study, we have demonstrated for the first
time that IL-1R2 is significantly increased in both plasma
and BAL fluid of ARDS patients as compared to healthy
subjects. Furthermore, we have shown that plasma IL-1R2
levels measured both early (within 96 h) and late (between
days 7–14) after the onset of ARDS significantly correlated
with APACHE scores at the time of presentation to
the hospital. Collectively, these findings suggest that
IL-1R2 reliably reflects the severity of systemic illness
in ARDS patients. Based on the well-established association
Figure 6 Linear regression of plasma and BAL fluid IL-1R2 (A-B) and S100A12 (C-D) levels of ARDS patients within day 0–3 of disease
onset as compared to APACHE score at initial presentation. (Linear regression slope is considered significant if p < 0.05).
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[42], it is not unreasonable to suspect that plasma IL-1R2
levels may be predictive of mortality in ARDS patients.
Although we did not see a significant correlation between
plasma IL-1R2 levels and mortality in the early stages ofFigure 7 Mean plasma IL-1R2 levels in ARDS survivors and
non-survivors at in days 0–3, days 4–6, and days 7–14 post ARDS
onset. Column means were analyzed by ANOVA with Dunnett’s multiple
comparisons test. (*p < 0.05 in non-survivors as compared to survivors).ARDS (≤6 days post onset), we did observe that mean
plasma IL-1R2 levels obtained later in the course of ARDS
(between days 7–14 post onset) were significantly higher
in non-survivors as compared to survivors, which sup-
ports an association between persistently high plasma
IL-1R2 levels and increased mortality. A larger study
would be required to detect correlations between IL-1R2
levels and other clinically significant outcomes.
Our study has several limitations. Importantly, our micro-
array analysis was limited to a single time point, which was
relatively early after the onset of ARDS (<96 h). Moreover,
the use of healthy subjects as a control group is not optimal.
Because of the small sample size, we were unable to
correlate changes in gene expression patterns with causes
of ARDS or certain clinical outcomes. However, we were
able to verify expression of protein corresponding to se-
lected over-expressed genes in both plasma and BAL fluid,
with a sample size large enough to show a significant
correlation to illness severity. Additionally, we have shown
for the first time the plasma IL-1R2 levels are elevated in
Kovach et al. Respiratory Research  (2015) 16:29 Page 13 of 14ARDS patients, and persistent elevations of this biomarker
correlate with increased mortality.
Conclusions
Taken together, our results show that both S100A12 and
IL-1R2 are potential biomarkers of ARDS that are present
in both the lung airspace and in circulation. This pilot
study provides important insights into ARDS pathogenesis,
including the identification of pathogenic molecules and
potential novel biomarkers in this disease.
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